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Approximately 2–3% of all newly diagnosed cancer in Sweden is
H&N cancer and its incidence is estimated to increase by approx-
imately 2% annually (Einhorn et al, 1996). Although tumour sites
(larynx, oral cavity, oropharynx, sinus and nose and the salivary
glands) are known to affect crucial functions, such as the ability to
breath, speak, eat and smell, until recently little has been known
about how such impairments impact on the HRQL of H&N cancer
patients. 
The first HRQL studies of H&N cancer patients were cross-
sectional or retrospective (Pruyn et al, 1986; de Boer et al, 1999),
but during the last few years prospective studies have also been
published (Jones et al, 1992; List et al, 1996; Deleyiannis et al,
1997; Funk et al, 1997; Hammerlid et al, 1997; Hammerlid et al.
1997; Morton, 1997; Hammerlid et al, 1998; Hammerlid et al,
1998; Bjordal et al, 1999; de Graeff et al, 1999; de Graeff et al,
1999; Deleyiannis et al, 1999; List et al, 1999; Rogers et al, 1999).
These studies have been performed with validated questionnaires
and have consistently shown that H&N cancer patients’ HRQL is
significantly below norm values at diagnosis and decreases during
and immediately after treatment. During this period, the patients
not only have major problems with pain and nutrition but are also
limited in daily physical and social functioning. However, within
the first year after diagnosis most of these mentioned
problems/functions return to their pretreatment values, except
symptoms and problems specifically related to treatment, such as
xerostomia and reduced taste and smell. On the other hand, mood
disorder, especially anxiety, have been found to be less common
one year after diagnosis (Hammerlid et al, 1999). 
In a study published by Funk (Funk et al, 1997), the HRQL of a
H&N cancer sample was compared with age-matched, US popula-
tion norms for the SF-36 (Ware et al, 1993). In this study, it was
shown that the H&N cancer patients (particularly the younger
ones) scored significantly lower for most on the HRQL domains
measured, both at diagnosis and after 6 months. 
Although the short-term and intermediate effects of H&N
cancer and its treatment are well documented, we know very
little about the HRQL of H&N cancer survivors more than 12
months after diagnosis. An important question is to what
degree they recover normal health status after rehabilitation,
i.e. how long-term H&N cancer survivors’ health status
compares with that of their contemporaries in the general popu-
lation. A study was therefore performed to examine the HRQL
of a large group of H&N cancer survivors 3 years after diag-
nosis compared with population norms. For this purpose, the
generic IQOLA SF-36 Health Survey was chosen with its
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1994). The secondary aim was to assess the specific tumour
burden and treatment side-effects. For this purpose, the EORTC
QLQ-C30 (Aaronson et al, 1993) and QLQ-H&N35 were used
(Bjordal et al, 1999). 
MATERIAL AND METHOD 
Study design 
Adult patients with diagnosed and untreated primary H&N cancer
(ICD-9 141–148, 160, 161 and 196) were invited consecutively to
participate in a longitudinal quality of life study at Sahlgrenska
University Hospital, Göteborg, during 1993–95. Survivors were
phoned 3 years after diagnosis and asked to complete the battery
of quality of life questionnaires once more. Patients disrupting the
previous study were also asked to participate. Those who were
unable to answer the HRQL questionnaires due to senile dementia,
mental disturbance or severe intercurrent disease were excluded.
No other exclusion criteria were used. 
Patients who agreed to participate were mailed the question-
naires. They were reminded once if they did not return the ques-
tionnaire within 10 days. 
Tumour location according to the ICD-9, TNM classification
(UICC-1987), treatment and clinical data including comorbidity
and Karnofsky Performance Status (Karnofsky et al, 1948) were
noted, together with the patient’s present tumour status. The study
was approved by the local ethics committee. 
QL questionnaires 
SF-36 health survey 
The SF-36 is a generic short-form measure of functional health
and well-being. It has been extensively applied in comparing
general and specific populations, estimating the burden of disease
and measuring the effectiveness of treatments (Ware and
Sherbourne 1992; Ware et al, 1993). The Swedish version was first
made available in 1992 and Swedish population norms were
published in 1994 (Sullivan et al, 1994, 1995). The questionnaire
consists of 8 health domains: physical health (10 questions), role
limitations due to physical problems (4 questions), bodily pain (2
questions), general health (5 questions), vitality (4 questions),
social functioning (2 questions), role limitations due to emotional
problems (3 questions), mental health (5 questions) and a question
about perceived change of health during the last year. A score
between 0 (worst) and 100 (best) is calculated for each domain
using a standardized scoring system (Ware et al, 1993). 
EORTC QLQ-C30 
This questionnaire (version 1.0) is a tumour-specific, patient-
based instrument designed for self-administration. The cross-
cultural validity and the psychometric properties are considered
satisfactory (Aaronson et al, 1993; Osoba et al, 1994; Hjermstad et
al, 1995). It has previously been used in HRQL studies of H&N
cancer (Bjordal and Kaasa 1992; Jones et al, 1992; Bjordal et al,
1994; Bjordal and Kaasa 1995; Bjordal et al, 1995; Hammerlid et
al, 1997a, 1997b; Hammerlid et al, 1998,a,b,c). The questionnaire
comprises 5 functional scales: physical functioning (5 questions),
role functioning (2 questions), emotional functioning (4 ques-
tions), cognitive functioning (2 questions) and social functioning
(2 questions). There are three symptom scales: fatigue (3 ques-
tions), nausea and vomiting (2 questions) and pain (2 questions)
and 6 single items relating to dyspnoea, insomnia, loss of appetite,
constipation, diarrhoea and financial difficulties. It also includes a
global health status/QL scale (2 questions). A one-week time
frame is employed. The HRQL scores are calculated according to
the EORTC QLQ-C30 scoring manual (Fayers et al, 1995). All
scales and single-item scores are transformed into a score from 0
to 100. A high score for a functional scale and for the global health
status/QL scale represents a high level of functioning, while a high
score for a symptom scale or single item represents a high level of
symptoms. 
EORTC QLQ-H&N35 
To measure symptoms and problems related to tumour location
and treatment, the EORTC head and neck cancer module, QLQ-
H&N35, was used (Bjordal et al, 1994, 1999). The instrument
comprises seven subscales: pain (4 questions), swallowing (5
questions), senses (2 questions), speech (3 questions), social
eating (4 questions), social contact (5 questions) and sexuality (2
questions). There are 10 single items relating to problems with
teeth, dry mouth, cough, opening the mouth wide, sticky saliva,
weight loss, weight gain, use of nutritional supplements, feeding
tubes and painkillers. 
In the present study an interim version of the module was used
because the final version was received after the start of this study.
The interim version differed from the final version in not including
a question on weight gain and the question about sticky saliva was
worded slightly different. The module is scored according to the
same scoring system as the EORTC QLQ-C30. 
Study-specific questionnaire 
This questionnaire contained 8 self-reported questions relating to
family situation, education, work and smoking habits. 
Reference samples 
Three different general population samples were used. 
(i) SF-36 reference group. An age and gender-matched sample
comprising 871 individuals was randomly selected from the
Swedish SF-36 normative database consisting of 8930 subjects
(Sullivan et al, 1994). 
(ii) EORTC QLQ-C30 reference group. Age and gender-adjusted
reference values (n = 276) for a Norwegian population sample
were obtained from published norm tables (Hjermstad et al,
1998a, b). The tables give mean scores for the total group, by
gender and by age group (10 year intervals), but do not
provide measures of variance. 
(iii) EORTC QLQ-H&N35 reference group. An age and 
gender-adjusted reference group (n = 270) from a population
sample from our own department was used. This population
sample consisted of 700 randomly selected inhabitants of
western Sweden. They answered the first 22 questions of the
EORTC QLQ-H&N 35 as part of an investigation on the
prevalence of dysphagia in the population (Hammerlid, 1997). 
Patients 
A total of 232 patients were included in the first part of the HRQL-
study 1993–95, 151 (65%) were alive 3 years after diagnosis. All
151 patients were found and contacted. Of these, 135 (89%) met
the inclusion criteria and agreed to take part in the study. The mean
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patients were female (31%). Less than half of the patients were
retired (n = 59, 44%) and 76 of the patients were less than 65 years
old (56%) at the time for diagnosis. 
The most common tumour site was the oral cavity (40 patients),
followed by the pharyngeal (35 patients), ‘other’ tumour sites
(salivary glands, unknown primary, sinus and nose carcinoma, 32
patients) and the larynx (28 patients). 
At the time of diagnosis 30% of the patients had a stage I
disease, 24% had stage II, 21% had stage III and 25% had stage IV
(stage was missing for 14 patients, the majority of whom had sinus
or nose carcinoma). Almost all patients (91%) had had radiation
therapy as part of their treatment and 37% of the patients had been
treated with interstitial radiation therapy. Chemotherapy had been
given to 34% of the patients (cis-platinol in combination with
5-flourouracil). The different combinations of treatment for the
entire study group and subgroups of patients are shown in Table 1. 
At the 3-year follow-up 126 of the patients had no signs of
relapse, 5 patients had been treated for a relapse but were tumour
free at the assessment point and 4 patients had an active disease
(one patient with oral cancer and 3 patients with ‘other tumours’). 
At the time of diagnosis 33% of the patients lived alone, 17%
had children living in their household, 39% were working, 51%
were retired and the rest were either unemployed, students or
homemakers (10%). 
8% of the patients had had a previous malignancy, 13% were
under treatment for heart disease, 7% for pulmonary disease and
18% for another disease. 
Statistical methods 
For descriptive purposes, we used means and 95% confidence
intervals for the mean. For comparisons between groups, Fisher’s
non-parametric permutation test was applied (Bradley, 1968).
Fisher’s exact test was used for comparison between proportions
and Pitman’s non-parametric permutation test for correlation
analysis (Bradley, 1968). The significance level was set at 5%
throughout. For each SF-36 scales a stepwise regression analysis
was performed with the SF-36 scales as dependent variables
and sex, age, disease, stage, tumour site and treatment as
independent. 
Strategy of analysis 
To aid in the interpretation of the results, clinical significance of
between-group differences is reported together with statistical
significance. Statistical and clinical significance are two very
distinct, yet equally important ways of interpreting group differ-
ences. Statistical significance refers to the probability that a
difference occurred by chance alone. In contrast, clinical signifi-
cance refers to the practical implications of the difference in terms
of its relative impact on health or well-being. Statistical signifi-
cance depends not only on the size of the difference between the
groups, but also on the amount of variation within the groups and
on the number of patients in the study. Thus, clinically trivial
differences can be statistically significant if, for example, the
sample size is sufficiently large, and conversely, clinically impor-
tant differences can be statistically non-significant if the study
lacks power. While standards for statistical significance have wide
acceptance and application, criteria for clinical significance are
less well-defined. We have applied criteria for interpreting score
differences that have been proposed for the instruments used in
this study. For the EORTC questionnaires, a 10 point change in
score has been suggested by King and Osoba (King, 1996; Osoba
et al, 1998) as clinically significant. The same criterion was used
both for the EORTC QLQ-C30 and EORTC QLQ-H&N35, even
though this criterion has been suggested only for the core ques-
tionnaire. For the SF-36, we used a 5 point difference as an indi-
cator of clinically and socially relevant change, as suggested by
Ware (Ware et al, 1993). 
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Table 1 Patient characteristics 
Sex Stage* Age 
All Female Male I + II III + IV <65 >65 
Number (%) 135 42 (31) 93 (69) 66 (55) 55 (45) 73 (57) 56 (43) 
Mean age 62 60 63 60 63 52 75 
Stage*
Stage I + II 66 (55) 23 (59) 43 (52) – – 38 (57) 25 (52) 
Stage III + IV 55 (45) 16 (41) 39 (48) – – 29 (43) 23 (48) 
Tumor site
Larynx 28 (21) 5 (12) 23 (25) 21 (30) 7 (13) 12 (16) 14 (25) 
Oral cavity 40 (30) 16 (38) 24 (26) 27 (41) 11 (20) 23 (32) 16 (29) 
Pharyngeal 35 (26) 11 (26) 24 (26) 9 (14) 26 (47) 23 (32) 9 (16) 
Other tumour sites 32 (23) 10 (24) 22 (23) 9(14) 11 (20) 15 (20) 17 (30) 
Treatment**
Surgery 11 (8) 6 (14) 5 (5) 7 (11) 1 (2) 6 (8) 5 (9) 
Radiation 39 (29) 7 (17) 32 (34) 32 (48) 7 (13) 18 (25) 18 (32) 
Rad+Surg 39 (29) 18 (43) 21 (23) 23 (35) 8 (14) 22 (30) 16 (29) 
Chemo+Rad+Surg 11 (8) 3 (7) 8 (9) 1 (1) 7 (13) 6 (8) 4 (7) 
Chemo+Rad 35 (26) 8 (19) 27 (29) 3 (5) 32 (58) 21 (29) 13 (23) 
Note: The number together with per cent in parentheses is given. Rad: Radiation therapy, Surg: Surgery, Chemo: Chemotherapy.*: Stage is missing for 
14 patients, ** Treatment, age < or > 65 years is missing for 6 patients. RESULTS 
Results from the SF-36 
Means and confidence intervals of the 8 SF-36 scales for the study
sample and reference group are shown in Table 2. The H&N
cancer patients scored worse or equal (-10–0 points) to the refer-
ence group on all domains, except bodily pain. The difference
was clinically relevant (³5 points) on two of the domains: the role-
physical functioning (s s10 points, P = 0.008) and the role-
emotional functioning (s s5 points, P = 0.11) but only the
role-physical functioning was statistically significant. 
Female and male patients versus population norms 
For the comparison of female cancer patients versus female refer-
ence data and male patients versus male reference data two new
groups of sex- and age-matched SF-36 normative data were used.
Female H&N cancer patients scored the same or better than the
reference group on all 8 SF-36 domains, Figure 1A. A clinically
and statistically significant difference between the two groups was
found for vitality (s s8 points, P = 0.05). The other domain with a
difference of ³5 points, bodily pain, was not statistically signific-
ant (P = 0.15). 
The opposite trend was found for the males, i.e. the population
sample scored better than the H&N cancer patients on 7 of the 8 SF-
36 scales, Figure 1B. The differences were clinically relevant for 5
and statistically significant for 4 of the scales. The largest difference
was found for role-physical functioning (s s15 points, P < 0.001),
followed by role-emotional functioning (s s8 points, P = 0.029),
physical functioning (s s7 points, P = 0.011), general health (s s6
points, P = 0.023) and social functioning (s s5 points, P = 0.064). 
Comparisons between male and female H&N cancer patients
showed females to score better than males on all scales except
mental health. Clinically important differences were found for
physical functioning, role-physical functioning, general health,
vitality and for role-emotional functioning but none was statist-
ically significant. 
In the stepwise regression analysis, gender was forced into the
model but did not explain a significant proportion of the variance
in any SF-36 scale. 
Patients below and above retirement age 
Figures 2A and 2B illustrate comparisons of patients below and
above retirement age (65 years) with SF-36 normative data for
sex- and age-matched subjects. 
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Table 2 Comparison of the results from the SF-36 for the study sample and the Swedish population 
H&N cancer patients Population sample P value
(n = 135) (n = 871) 
Physical functioning 75 (71–80) 79 (77–81) 0.110 
Role-physical functioning 64 (57–71) 74 (71–76) 0.008 
Bodily pain 73 (69–77) 71 (69–72) 0.346 
General health 67 (63–71) 70 (69–72) 0.077
Vitality 67 (63–72) 67 (66–69) 0.985 
Social functioning 84 (80–88) 87 (86–89) 0.140 
Role-emotional functioning 77 (70–84) 82 (80–84) 0.119 
Mental health 79 (75–82) 81 (79–82) 0.328
The table shows mean values with 95% confidence intervals. n = number of patients. 
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Figure 1A The results from the SF-36 for female H&N cancer patients
(n = 42) 3 years after diagnosis compared to age-matched female normative
data. The higher the score, the better functioning. PF = Physical functioning,
RP = Role-Physical, BP = Bodily Pain, GH = General Health, VT = vitality,
SF = Social Functioning, RE = Role-Emotional, MH = Mental Health
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Figure 1B The results from the SF-36 for male H&N cancer patients
(n = 93) 3 years after diagnosis compared to age-matched male normative
data. The higher the score, the better functioning. PF = Physical
Functioning, RP = Role-Physical, BP = Bodily Pain, GH = General Health,
VT = vitality, SF = Social Functioning, RE = Role-Emotional, MH = Mental
HealthScores for patients below retirement age were similar to
reference values (± s s4 points) on all scales except role-physical
functioning (-s s12 points, P = 0.012) where the H&N cancer
patients scored worse and bodily pain (+s s5 points, P = 0.117)
where the cancer patients scored better. Comparisons between
retired patients and their counterparts in the reference sample
revealed clinically important differences in favour of the reference
group on 5 of the 8 scales but only one was statistically significant.
The largest score differences were found for role-physical func-
tioning (-s s9 points, P = 0.110) and social functioning (-s s8
points, P = 0.020). Other clinically relevant differences (³5 points)
were found for role-emotional functioning, general health and
vitality, but these were not statistically significant. 
Different tumour sites and stage 
Clinically important differences between the worst and best SF-36
scales scores were found when the different tumour sites were
compared (Table 3). The role-physical functioning and role-
emotional functioning varied most. Laryngeal cancer patients
scored highest on 4 of the scales (mental health related) while the
oral cancer group scored worst on 3. 
Only a few clinical relevant differences were noted between
patients with small (stage I+II) and large (stage III+IV) tumours
(Table 3). Patients with small tumours scored higher on the bodily
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Table 3 Results from the SF-36 for subgroups of head and neck cancer patients three years after diagnosis 
Tumour site Stage 
Larynx Oral cavity Pharyngeal Other I+II III+IV 
(n = 28) (n = 40) (n = 35) (n = 32) (n = 66) (n = 55) 
Physical functioning 74 (63–85) 75 (67–84) 75 (66–84) 77 (67–86) 74 (67–81) 76 (70–83) 
Role-physical functioning 63 (46–79) 63 (48–77) 71 (57–85) 59 (43–74) 63 (53–74) 65 (53–77) 
Bodily pain 76 (66–86) 71 (62–80) 78 (63–81) 74 (66–83) 76 (69–82) 70 (63–76)
General health 66 (56–76) 68 (60–76) 66 (57–75) 66 (59–74) 68 (62–75) 65 (59–71)
Vitality 71 (60–81) 66 (58–74) 67 (57–76) 67 (60–74) 68 (62–75) 68 (61–74)
Social functioning 90 (85–96) 81 (72–91) 81(74–89) 85 (78–92) 84 (78–90) 84 (78–90)
Role-emotional functioning 83 (69–97) 77 (63–91) 78 (65–91) 72 (58–87) 76 (66–87) 79 (70–89) 
Mental health 83 (75–90) 76 (69–83) 78 (70–85) 80 (74–86) 82 (76–85) 77 (71–83
The table shows the mean values and 95% confidence intervals. n = number of patients. 
Table 4 Results from the EORTC QLQ-H&N35. A comparison of the head
and neck cancer patients with a sample from the Swedish population 
H&N cancer  Population  P value
patients sample
(n = 135) (n = 270) 
H&N35 scales
Pain 14 (11–18) 3 (2–4) <0.0001 
Swallowing 11 (7–14) 3 (2–4) <0.0001 
Senses 20 (16–25) 3 (2–5) <0.0001 
Social eating 11 (8–15) 1 (1–2) <0.0001
H&N35 single items
Problems with teeth 21 (15–26) 12 (9–15) <0.01 
Opening mouth wide 17 (12–22) 1 (0–2) <0.0001 
Dry mouth 47 (41–53) 17 (14–20) <0.0001
Mucus production 18 (13–23) 7 (5–9) <0.0001 
Cough 17 (13–21) 19 (16–22) 0.79 
Feeling ill 11 (7–14) 10 (7–12) 0.34 
The table shows mean values with 95% confidence intervals. The higher the
score, the more problems. n = number of patients. 
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Figure 2A The results from the SF-36 for H&N cancer patients >65 years 3
years after diagnosis compared to age- and sex-matched normative data.
The higher the score, the better functioning. PF = Physical Functioning,
RP = Role-Physical, BP = Bodily Pain, GH = General Health, VT = vitality,
SF = Social Functioning, RE = Role-Emotional, MH = Mental Health 
PF
H&N cancer patients <65 years
B
Normative data
0
10
20
30
40
50
60
70
80
90
RP BP GH VT SF RE MH
Figure 2B The results from the SF-36 for H&N cancer patients < 65 years 3
years after diagnosis compared to age- and sex-matched normative data. The
higher the score, the better functioning. PF = Physical Functioning, RP = Role-
Physical, BP = Bodily Pain, GH = General Health, VT = vitality, SF = Social
Functioning, RE = Role-Emotional, MH = Mental Health pain and mental health scales (+s s6 respectively +s s5 points) but
these differences were not statistically significant. 
Results from the EORTC QLQ-C30 and QLQ-H&N35 
The results from the EORTC QLQ-H&N35 are shown in Table 4.
The H&N cancer patients scored significantly worse compared to
the population sample on all scales and single items examined,
except for cough and feeling ill. Most of the differences were both
clinically (difference ³10 points) and statistically significant. The
largest differences were found for dry mouth, senses and opening
the mouth wide. 
In order to corroborate the gender differences found for the
SF-36, the results from the EORTC QLQ-C30 for the females and
males were compared with Norwegian reference data (Table 5).
These reference data were only available for certain age groups
(Hjermstad et al, 1998). Age 60–69 was chosen for comparison
since the mean age in the patient sample was 60 and 63 for the
females and males, respectively. 
The female cancer patients scored better on 13 of the 15 scales
and single items in the QLQ-C30 compared to the female refer-
ence data. Five of the scores showed a clinically significant differ-
ence (ù10 points) in favour of the cancer patients: physical
functioning, fatigue, dyspnoea, insomnia and pain. 
The male cancer patients scored better on 7 of the 15 scales and
items compared to the reference data but none of the differences
reached ³10 points. 
When the scores were compared between the female and male
cancer patients, the females scored better on 11 of the 15 scales
and single items but only the difference on dyspnoea was clinically
important. 
DISCUSSION 
Previous research has shown that the HRQL of H&N cancer
patients is poor at diagnosis compared to a normative population
sample (Funk et al, 1997) and deteriorates during and immediately
after treatment. However, within a year after diagnosis most of the
general functions and treatment-related side-effects return to their
pre-treatment values (Hammerlid et al, 1997a,b, 1998, 1999; de
Graeff et al, 1999a,b). Little is known about this patient group
beyond one year post-diagnosis. Consequently, this study was
conducted to evaluate the long-term (3 years) HRQL of H&N
cancer survivors to determine if their levels of mental and physical
functioning are comparable to population norms. 
In general, the results of this study indicate that the general
health status of long-term H&N cancer survivors is comparable to
that of age-and gender-matched population norms. Only one of the
8 SF-36 health domains differed significantly from the norm and
none of the domains measured by the cancer-specific EORTC
QLQ-C30 showed clinically important deviations below the refer-
ence values (Tables 2 and 5). 
On the other hand, gender comparisons with normative data
revealed some interesting and unexpected results. The female
cancer patients tended to score better than female norms, both on
the SF-36 and the EORTC QLQ-C309 (Figure 1A and Table 5)
while the male H&N cancer patients reported worse HRQL for the
majority of scales than male norms for the SF-36 and EORTC
QLQ-C30 (Figure 1B and Table 5). The differences between the
male cancer patients and the male normative group were signific-
ant for most of SF-36 scales. 
When the females and males were compared, the females had a
tendency to score better than the males. These findings were also
unexpected since females have been consistently shown to report
poorer HRQL than males in both general populations and in
different clinical groups (Sullivan et al, 1994; Chin and Goldman,
1998; Hjermstad et al, 1998; Osborne et al, 1998). Consequently, it
was considered important to see if the patients’ gender was a
major determinant of reported health status, or if the effects of
gender were confounded by other variables, especially since males
and females differed in mean age and distribution of tumour sites
and treatment modality. As a first step, baseline male and female
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Table 5 A comparison between the female and male head and neck cancer patients and Norwegian population values 
Female Male 
Cancer patients Population sample Cancer patients Population sample 
n 42 142 93 134 
Age mean 60 60–69 mean 63 60–69 
Functional scales* 
Physical functioning 89 (82–96) 78 85 (80–89) 89 
Role functioning 87 (78–96) 89 83 (77–89) 90 
Social functioning 91 (85–97) 83 86 (81–90) 81 
Emotional functioning 85 (79–91) 83 86 (82–90) 85 
Cognitive functioning 91 (86–96) 86 86 (83–96) 83 
Global quality of life 74 (66–81) 69 73 (69–78) 74 
Symptom scales/single items** 
Fatigue 18 (10–25) 33 24 (20–29) 24 
Pain 12 (5–18) 32 16 (12–21) 21 
Nausea and vomiting 2 (0–4) 4 3 (1–4) 2 
Dyspnoe 10 (4–16) 20 20 (15–25) 16 
Insomnia 18 (9–26) 33 18 (13–23) 19 
Loss of appetite 15 (6–23) 6 10 (5–15) 4 
Constipation 15 (5–23) 16 9 (5–15) 9 
Diarrhoea 2 (0–4) 9 5 (2–18) 8 
Financial difficulties 9 (3–15) 12 12 (6–17) 13 
Note: *Higher score means better functioning. **Higher score means more problems. 
n = number of patients. scores on the EORTC QLQ-C30 and QLQ-H&N35 (SF-36 was
not a baseline instrument) were compared to see if they differed at
outset. At diagnosis, the males scored better on 10 of the 15
EORTC QLQ-C30 scales and single items, with clinically signific-
ant differences on emotional functioning and appetite loss (data
not shown). On the H&N module, the only significant difference
was on sexual functioning, where the males again scored better.
No differences could be found regarding the incidence of
comorbid conditions. Stepwise regression analyses were then
performed with each of the 8 SF-36 scales as dependent variables
and sex, age, disease stage, tumour site, treatment modality and
number of comorbidities as independents. Although sex was
forced into each of the models, it could not account for a signifi-
cant proportion of the variance in any of the SF-36 scales. In fact,
none of the background variables contributed more than 4% of the
variance in any scale. Thus, although the females, on average,
reported better health status than their male counterparts at follow-
up, other (unexplained) factors besides gender determined the SF-
36 scale scores. Further research with a larger study group should
be conducted to identify such factors. 
Almost all functions and problems measured by the H&N cancer-
specific EORTC QLQ-H&N35 were significantly worse for the
H&N cancer patients than the population sample (Table 4). Thus,
despite significant problems with important functions like swal-
lowing, social eating and localized pain, the patients reported normal
general functioning and mental health 3 years after diagnosis. 
A possible explanation for this apparent incongruity between
general health status and H&N cancer-related limitations/problems
reported by H&N cancer survivors concerns the inherent differ-
ences between disease-specific versus generic health status instru-
ments. As the name implies, disease-specific instruments, such as
the EORTC QLQ-H&N35, are designed to tap symptoms, prob-
lems and limitations distinctly associated with a particular disease,
while generic instruments, such as the SF-36, cover general health
domains found important and applicable in general populations.
The two thus contribute complementary information on different
aspects of overall health status. Where the first is sensitive to
specific disease or treatment burdens, the second informs about the
impact of such burdens on the patient’s overall physical func-
tioning and mental well-being. In other words, although the H&N
cancer patients in this study still experience considerable problems
directly associated with their disease and/ or its treatment, they
have successfully adjusted to living with their problems and thus
assess their overall physical and mental health at levels com-
parable to norms. 
The pain scales common to the 3 instruments may be used to
illustrate the inherent differences between disease-specific versus
generic health status instruments. On the EORTC QLQ-H&N35
the patients reported significantly more pain than the population,
while on both the SF-36 and EORTC QLQ-C30 they scored at or
better than norm levels (Tables 2, 4 and 5). The first instrument
assesses the intensity of pain localized to the head and neck region,
while in the EORTC QLQ-C30 and SF-36 questions are asked
about both the intensity of non-specified pain and its impact on
one’s ability to work or perform daily activities. This may be inter-
preted to mean that although the patients suffer from substantial
localized pain, it does not interfere with the performance of their
daily activities. It is important to note, however, that the cancer
patients scored worse than the norm on the SF-36 role physical
functioning scale (Table 2). This implies that the patients felt
limited, for reasons other than pain, by their physical health in
carrying out daily activities. 
In a previous study of mental health in head and neck cancer
patients the prevalence of depression was reported to be 17–29%
one year after diagnosis (Hammerlid et al, 1999). After an initial
period of deterioration during and just after treatment, patients
tended to report improved mental health at 6 months and fully
return to pre-treatment levels at 12 months (Funk et al, 1997;
Hammerlid et al, 1999). Our results are optimistic in that they indi-
cate that in the long-term mental health continues to improve,
reaching levels corresponding to norms for the general population. 
Another finding was that disease stage at diagnosis had little
impact on the HRQL after 3 years later (Table 3). This result was
unexpected since in our previous studies, patients with more
advanced diseases (Stage III or IV) had worse HRQL at diagnosis
and after one year than Stage I & II patients (Hammerlid et al,
1997, 1998). However, these studies have also shown that patients
who died within the first year after diagnosis, had scored signifi-
cantly worse than survivors on the majority of domains, already at
diagnosis. Thus, it is likely that this finding simply reflects the fact
that patients who scored worst at diagnosis, i.e. patients with Stage
III+IV and those with progressive disease and relapses, had died
during the follow-up period. 
All but the physical functioning and general health scales varied
between tumour sites, Table 3. The laryngeal cancer patients had a
tendency to score slightly better on all four of the SF-36 mental
health scales. This may possibly be explained by the fact that most
(75%) laryngeal tumours were discovered at an early stage and
could therefore be treated with one modality (radiation therapy). 
Older patients (>65 years) scored worse than norms on all SF-36
scales, while younger patients had values equal to or better than
norms on all but three scales (Figures 2A and B). Funk et al have
previously shown that head and neck cancer patients scored worse
for the majority of SF-36 domains compared to SF-36 normative
data at diagnosis and 6 months and that the difference was larger
between the younger patients and reference data than for the older
(Funk et al, 1997). The result in this study is, however, in line with a
previous longitudinal HRQL study using the EORTC QLQ-C30 and
QLQ-H&N35 (Hammerlid, Head and Neck, in press) and confirms
results from an earlier study (Terell et al, 1999). In the first study we
found that the younger patients (<65 years) improved more during
the 3 year long observation period than the older patients, i.e. they
seem to have a better rehabilitation potential. The discrepancy
between the results of this study and Funk’s might therefore be
explained by the difference in length of follow-up. 
CONCLUSION 
Three years after diagnosis the overall quality of life of the H&N
cancer patients, measured by the SF-36, was generally comparable
to age- and sex-matched normative values for the Swedish popula-
tion. However, H&N cancer patients reported significantly more
role limitations due their physical health, as well as more
disease/treatment-related symptoms and problems. 
We therefore conclude that despite enduring and possibly
lifestyle-limiting problems/symptoms related to H&N cancer and
its treatment, the physical and mental health reported by H&N
cancer survivors is otherwise unencumbered 3 years after diag-
nosis compared to their counterparts in the general population –
largely irrespective of tumour site or disease stage. 
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